Urocortin 2 sustains haemodynamic and renal function during introduction of beta-blockade in experimental heart failure

Journal of Hypertension

Volumn 29, Issue 9, 2011, Pages 1787-1795

  Rademaker, Miriam T ^a   Charles, Christopher J ^a   Nicholls, Gary ^a   Richards, Mark ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

acute decompensated heart failure; beta adrenergic receptor blocker; haemodynamics; renal function; urocortin 2

Indexed keywords

ALDOSTERONE; CREATININE; METOPROLOL; RENIN; SODIUM; UROCORTIN II;

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATININE CLEARANCE; CREATININE URINE LEVEL; DRUG POTENTIATION; HEART HEMODYNAMICS; HEART LEFT ATRIUM PRESSURE; HEART LEFT VENTRICLE CONTRACTION; HEART OUTPUT; HEART PACING; HEART RATE; KIDNEY FUNCTION; MEAN ARTERIAL PRESSURE; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; SHEEP; SODIUM EXCRETION; URINE VOLUME; VASCULAR RESISTANCE;

EID: 80051916123     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283493776     Document Type: Article

References (34)

1. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117:e25-e146.
2. Fonarow GC, Corday E. ADHERE. Scientific Advisory Committee. Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry. Heart Fail Rev 2004; 9:179-185. (Pubitemid 40521279)
3. Packer M. Current role of beta-adrenergic blockers in the management of chronic heart failure. Am J Med 2001; 110:S81-S94.
4. Vilas-Boas F. Modern approach to the treatment of decompensated heart failure. Expert Rev Cardiovasc Ther 2009; 7:159-167.
5. Dec GW. Management of acute decompensated heart failure. Curr Probl Cardiol 2007; 32:321-366. (Pubitemid 46776868)
6. Metra M, Torp-Pedersen C, Cleland JG, Di Lenarda A, Komajda M, Remme WJ, et al. COMET investigators. Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. Eur J Heart Failure 2007; 9:901-909. (Pubitemid 47332312)
7. Gattis WA, O'Connor CM. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure. Am J Cardiol 2004; 93:74B-76B. (Pubitemid 38624277)
8. Fares WH. Management of acute decompensated heart failure in an evidence-based era: what is the evidence behind the current standard of care? Heart Lung 2008; 37:173-178. (Pubitemid 351636331)
9. Teerlink JR, Metra M, Zaca V, Sabbah HN, Cotter G, Gheorghiade M, Cas LD. Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond. Heart Fail Rev 2009; 14:243-253.
10. Goebel JA, Van Bakel AB. Rational use of diuretics in acute decompensated heart failure. Curr Heart Fail Rep 2008; 5:153-162.
11. Hsu SY, Hsueh AJ. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 2001; 7:605-611. (Pubitemid 32448329)
12. Wiley KE, Davenport AP. CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators. Br J Pharmacol 2004; 143:508-514. (Pubitemid 39452218)
13. Bale TL, Hoshijima M, Gu Y, Dalton N, Anderson KR, Lee KF, et al. The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. Proc Natl Acad Sci USA 2004; 101:3697-3702. (Pubitemid 38338257)
14. Rademaker MT, Cameron VA, Charles CJ, Richards AM. Integrated hemodynamic, hormonal and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure. Circulation 2005; 112:3624-3632. (Pubitemid 43739541)
15. Davis ME, Pemberton CJ, Yandle TG, Fisher SF, Lainchbury JG, Frampton CM, et al. Urocortin 2 infusion in healthy humans hemodynamic, neurohormonal, and renal responses. J Am Coll Cardiol 2007; 49:461-471. (Pubitemid 46135883)
16. Davis ME, Pemberton CJ, Yandle TG, Fisher SS, Lainchbury JG, Frampton CM, et al. Urocortin 2 infusion in human heart failure. Eur Heart J 2007; 28:2589-2597. (Pubitemid 350071510)
17. Fitzpatrick MA, Nicholls MG, Espiner EA, Ikram H, Bagshaw P, Yandle TG. Neurohumoral changes during the onset and offset of ovine heart failure: role of ANP. Am J Physiol 1989; 256:H1052-H1059.
18. Rademaker MT, Charles CJ, Espiner EA, Frampton CM, Nicholls MG, Richards AM. Natriuretic peptide responses to acute and chronic pacing in sheep. Am J Physiol 1996; 270:H594-H602.
19. Rademaker MT, Charles CJ, Richards AM. Urocortin 1 administration from the onset of rapid left ventricular pacing represses progression to overt heart failure. Am J Physiol 2007; 293:H1536-H1544. (Pubitemid 47367198)
20. Rademaker MT, Charles CJ, Nicholls MG, Richards AM. Urocortin 2 combined with angiotensin-converting enzyme inhibition in experimental heart failure. Clin Sci 2008; 114:635-642. (Pubitemid 351589062)
21. Rademaker MT, Charles CJ, Nicholls MG, Richards AM. Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure. Circ Heart Failure 2009; 2:532-540.
22. Ellmers LJ, Carter E, Scott NJA, Richards AM, Cameron VA, Rademaker MT. Urocortin 2 treatment reduces genes involved in cardiac remodelling in an ovine model of heart failure. Eur Heart J 2009; 30:(Abstract Supplement) 288 in press.
23. Charles CJ, Jardine DL, Rademaker MT, Richards AM. Urocortin 2 induces potent long-lasting inhibition of cardiac sympathetic drive despite baroreflex activation in conscious sheep. J Endocrinol 2010; 204:181-189.
24. Parkes DG. Cardiovascular actions of CRH and urocortin: an update. Peptides 2001; 22:821-827. (Pubitemid 32397734)
25. Grossini E, Molinari C, Mary DA, Marino P, Vacca G. The effect of urocortin II administration on the coronary circulation and cardiac function in the anaesthetized pig is nitric-oxide-dependent. Eur J Pharmacol 2008; 578:242-248. (Pubitemid 350309583)
26. Gardiner SM, March JE, Kemp PA, Bennett T. A comparison between the cardiovascular actions of urocortin 1 and urocortin 2 (stresscopin-related peptide) in conscious rats. J Pharmacol Exp Therapeut 2007; 321:221-226. (Pubitemid 46456961)
27. Yao X, He GW, Chan FL, Lau CW, Tsang SY, Chen ZY, Huang Y. Endothelium-dependent and independent coronary relaxation induced by urocortin. J Cardiac Surgery 2002; 17:347-349. (Pubitemid 36071992)
28. Gardiner SM, March JE, Kemp PA, Davenport AP, Wiley KE, Bennett T. Regional hemodynamic actions of selective corticotropin-releasing factor type 2 receptor ligands in conscious rats. J Pharmacol Exp Therapeut 2005; 312:53-60. (Pubitemid 40096452)
29. Meili-Butz S, Buhler K, John D, Buser P, Vale WW, Perterson KL, et al. Acute effects of urocortin 2 on cardiac function and propensity for arrhythmias in an animal model of hypertension-induced left ventricular hypertrophy and heart failure. Eur J Heart Fail 2010; 12:797-804.
30. Liu CN, Yang C, Liu XY, Li S. In vivo protective effects of urocortin on ischemia-reperfusion injury in rat heart via free radical mechanisms. Can J Physiol Pharmacol 2005; 83:459-465. (Pubitemid 41176363)
31. Tao J, Xu H, Yang C, Liu CN, Li S. Effect of urocortin on L-type calcium currents in adult rat ventricular myocytes. Pharmacol Res 2004; 50:471-476. (Pubitemid 39349047)
32. Scarabelli TM, Pasini E, Stephanou A, Comini L, Curello S, Raddino R, et al. Urocortin promotes hemodynamic and bioenergetic recovery and improves cell survival in the isolated rat heart exposed to ischemia/reperfusion. J Am Coll Cardiol 2002; 40:155-161. (Pubitemid 34701391)
33. Chanalaris A, Lawrence KM, Stephanou A, Knight RD, Hsu SY, Hsueh AJ, Latchman DS. Protective effects of the urocortin homologues stresscopin (SCP) and stresscopin-related peptide (SRP) against hypoxia/reoxygenation injury in rat neonatal cardiomyocytes. J Mol Cell Cardiol 2003; 35:1295-1305. (Pubitemid 37163536)
34. Abdelrahman AM, Lin Lim S, Pang CC. Influence of urocortin and corticotropin releasing factor on venous tone in conscious rats. Eur J Pharmacol 2005; 510:107-111. (Pubitemid 40312395)